AG真人官方

Kurian George, a director of The Cigna Group (CI), reported a compensation deferral into the company鈥檚 deferred compensation plan on 08/29/2025. The filing shows an acquisition of 99.7109 phantom stock units under the Deferral Plan at a recorded price of $300.87 per unit; each phantom unit is economically equivalent to one share of Cigna common stock and will be settled in cash. After the transaction the report shows 1,574.5491 shares (or phantom-equivalent units) beneficially owned by the reporting person, which includes 7.0495 units received via dividend reinvestment. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/02/2025.

David J. Brailer, EVP & Chief Health Officer of The Cigna Group (CI), reported a transaction on 08/29/2025 showing 290 shares of Cigna common stock were disposed of at a price of $300.66 per share. The filing states these shares were withheld to satisfy tax obligations upon the vesting of restricted shares, not a market sale.

After the withholding, Mr. Brailer beneficially owns 17,525 shares of Cigna common stock. The Form 4 was executed by an attorney-in-fact and filed on 09/02/2025.

The Cigna Group prospectus supplement describes an offering of multiple series of senior unsecured notes (the "Notes") with various maturities and interest rates, to be issued in book-entry form through DTC and delivered on or about September 2025. Interest will accrue from 2025 and is payable semiannually beginning in 2026. The Notes are senior, unsecured and unsubordinated, rank equally with other senior unsecured indebtedness, will be structurally subordinated to subsidiary liabilities and effectively junior to secured debt to the extent of collateral. The issuer may optionally redeem the Notes under specified terms and must offer to repurchase Notes at 101% upon a change of control triggering event. The prospectus discusses tax treatment, DTC mechanics, events of default, amendment mechanics, defeasance options and ERISA considerations.

The Cigna Group registers securities for public offering and describes terms applicable to debt securities, trustee rights, defaults and amendment mechanics. The prospectus outlines the specific items that will be set for each debt series, including interest rates, payment dates, redemption and conversion features, denominations, currencies, paying agents and any sinking-fund or prepayment provisions. It explains Events of Default (missed payments, covenant breaches, insolvency) and holders' remedies, including acceleration subject to majority rescission rights.

The document clarifies that debt may be fungibly reissued, that most amendments require a majority of affected holders but certain changes need unanimous consent, and that debt securities generally do not include change-of-control repurchase rights unless stated in a prospectus supplement. It also covers defeasance options, transfer agent (Computershare), NYSE listing (CI), ERISA considerations for plan investors, indemnification of directors and officers and reliance on PwC for audited financials.

Nicole S. Jones, EVP, Chief Administrative Officer and General Counsel of The Cigna Group (CI), reported multiple transactions under a Rule 10b5-1 plan. On 08/15/2025 and 08/18/2025 she executed option exercises and open-market trades: option-related acquisitions of 13,155 and 11,598 shares at exercise prices of $197.35 and $183.4405, additional option exercises of 1,348 and 1,329 shares, and a reported sale of 28,526 shares at $300 on 08/15/2025. Following these transactions her reported beneficial ownership positions changed across reported lines (examples shown: 42,576; 54,174; 25,648; 26,996; 28,325). She also holds 1,419.6518 shares indirectly via the company 401(k) plan. The Form 4 states the trades were effected pursuant to a 10b5-1 plan adopted May 8, 2025, and lists Tyler Gratton as attorney-in-fact who signed the filing on 08/19/2025.

Form 144 filing for Cigna (CI) reports a proposed sale of 28,526 common shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $8,557,800 and approximately 266,928,075 shares outstanding. The shares to be sold were acquired via restricted stock vesting (1,137 shares on 03/01/2024) and option exercises or option-related transactions (2,636 shares on 08/13/2024; 13,155 shares and 11,598 shares with dates shown as 08/15/2025 tied to options granted in 2018 and 2019). No securities were reported sold in the past three months. The filer attests they are not aware of any material nonpublic information.

Cigna Group (CI) submitted a Form 144 proposing the sale of 35,711 shares of its common stock, with an aggregate market value of $9,822,667.66, to be executed on 08/12/2025 through Fidelity Brokerage Services LLC on the NYSE. The filing lists total shares outstanding of 266,928,075 and shows the securities to be sold were acquired through option exercises and restricted stock vesting between 02/26/2021 and 08/12/2025, with some purchases paid in cash and others issued as compensation.

The filer reports no securities sold by the same person in the past three months and includes the standard attestation that the seller has no undisclosed material information; the notice is marked LIVE.